ATE378067T1 - Agent zur induktion einer immunologischen toleranz - Google Patents

Agent zur induktion einer immunologischen toleranz

Info

Publication number
ATE378067T1
ATE378067T1 AT99938639T AT99938639T ATE378067T1 AT E378067 T1 ATE378067 T1 AT E378067T1 AT 99938639 T AT99938639 T AT 99938639T AT 99938639 T AT99938639 T AT 99938639T AT E378067 T1 ATE378067 T1 AT E378067T1
Authority
AT
Austria
Prior art keywords
agent
immunological tolerance
inducing immunological
autoimmune diseases
diseases
Prior art date
Application number
AT99938639T
Other languages
English (en)
Inventor
Ho-Youn Kim
Jong-Sang Park
Zae-Young Ryoo
Euiyoung Bae
Woo-Kyoung Lee
Chul-Soo Cho
Sung-Hwan Park
Wan-Uk Kim
Original Assignee
Industy Academic Cooperation F
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Industy Academic Cooperation F filed Critical Industy Academic Cooperation F
Application granted granted Critical
Publication of ATE378067T1 publication Critical patent/ATE378067T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT99938639T 1999-08-18 1999-08-18 Agent zur induktion einer immunologischen toleranz ATE378067T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR1999/000460 WO2001012222A1 (en) 1999-08-18 1999-08-18 Immunological tolerance-induction agent

Publications (1)

Publication Number Publication Date
ATE378067T1 true ATE378067T1 (de) 2007-11-15

Family

ID=19570981

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99938639T ATE378067T1 (de) 1999-08-18 1999-08-18 Agent zur induktion einer immunologischen toleranz

Country Status (6)

Country Link
EP (1) EP1212086B8 (de)
JP (1) JP3926626B2 (de)
AT (1) ATE378067T1 (de)
AU (1) AU5307899A (de)
DE (1) DE69937580D1 (de)
WO (1) WO2001012222A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003082269A1 (en) * 2002-03-29 2003-10-09 The Board Of Trustees Of The Leland Stanford Junior University Use of statins and other immunomodulatory agents in the treatment of autoimmune disease
AU2002352938B8 (en) 2002-11-26 2009-10-08 The University Of Chicago Materials and methods for preventing and treating microbe-mediated epithelial disorders
JP2008297204A (ja) * 2007-05-29 2008-12-11 Masahiro Murakami ポリ乳酸混合物を含む肝繊維化の抑制又は改善剤
DE102007039446A1 (de) 2007-08-21 2009-02-26 Volkswagen Ag Verfahren zum Anzeigen von Informationen in einem Kraftfahrzeug mit veränderbarem Maßstab und Anzeigeeinrichtung
US11041013B2 (en) 2008-03-14 2021-06-22 Cel-Sci Corporation Methods of preparation and composition of peptide constructs useful for treatment of rheumatoid arthritis
CN102573802A (zh) * 2009-08-12 2012-07-11 希格默伊德药业有限公司 包含聚合物基质和油相的免疫调节组合物
AU2011325966B2 (en) * 2010-11-12 2016-09-29 Oncour Pharma, Inc. Modified immune-modulating particles
WO2012162564A1 (en) 2011-05-25 2012-11-29 Cel-Sci Corporation Method for inducing an immune response and formulations thereof
CN110064049B (zh) 2012-06-21 2024-02-09 西北大学 肽缀合粒子
EP3494966B1 (de) 2013-03-13 2024-04-03 onCOUR Pharma, Inc. Immunmodifizierende partikel zur behandlung von entzündungen
KR20160042079A (ko) 2013-08-13 2016-04-18 노쓰웨스턴유니버시티 펩티드-접합된 입자
CN111109198B (zh) * 2019-03-29 2021-08-20 成都华西海圻医药科技有限公司 一种葡萄膜炎动物模型构建方法
CA3140649A1 (en) * 2019-05-16 2020-11-19 Arizona Board Of Regents On Behalf Of Arizona State University Metabolite delivery for modulating metabolic pathways of cells
US20220280557A1 (en) * 2019-09-12 2022-09-08 Arizona Board Of Regents On Behalf Of Arizona State University Metabolic Reprogramming of Immune Cells for the Treatment or Prevention of Diseases and Disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012529A1 (en) * 1992-12-03 1994-06-09 The Regents Of The University Of California Improved reagents and methods for the diagnosis and treatment of diabetes and stiff man syndrome
IS4518A (is) * 1997-07-09 1999-01-10 Lyfjathroun Hf, The Icelandic Bio Pharmaceutical Group Nýtt lyfjaform fyrir bóluefni
US6312731B1 (en) * 1997-08-29 2001-11-06 Southern Research Institute Rapid release encapsulated bioactive agents for inducing or potentiating an immune response and methods of using thereof
WO1999037315A1 (en) * 1998-01-27 1999-07-29 Bai Jane Pei Fan Chemical derivatives of autoantigens and autoimmune-suppressive peptides and pharmaceutical composition containing the same

Also Published As

Publication number Publication date
JP3926626B2 (ja) 2007-06-06
EP1212086A1 (de) 2002-06-12
EP1212086B1 (de) 2007-11-14
AU5307899A (en) 2001-03-13
JP2003507340A (ja) 2003-02-25
DE69937580D1 (de) 2007-12-27
WO2001012222A1 (en) 2001-02-22
EP1212086B8 (de) 2008-01-02

Similar Documents

Publication Publication Date Title
DE69937580D1 (de) Agent zur induktion einer immunologischen toleranz
WO2001085154A3 (en) Method of treating immune pathologies with low dose estrogen
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
FI963101A0 (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
BR9814393A (pt) Micropartìculas e uso terapêutico ou diagnóstico delas
ATE237330T1 (de) Verabreichung von nikotin im dickdarm zur behandlung von entzündlicher eingeweidenerkrankung
ATE365540T1 (de) Behandlung akuter gesundheitsstörungen durch die sublingual verabreichung einer pharmazeutischen zusammensetzung
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
TR199701490A2 (xx) 3-Hidroksipiridin-2-karbonasitamidester ve bunlar�n imalat�.
FI963049L (fi) Progesteroniantagonisteja lääkeaineiden valmistamiseksi, jotka on tarkoitettu kohdun toimintahäiriöistä johtuvien verenvuotojen hoitamiseksi
SE9602931D0 (sv) New medicinal use
CA2452986A1 (en) Use of polyclonal anti-hiv goat serum as a therapeutic agent
EP1578373A4 (de) Neue zusammensetzungen und verfahren zur behandlung von erkrankungen des immunsystems
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
EP1093816A3 (de) Verwendung von ST1435 in Hormonaltherapie durch transdermale Verabreichung
PT862454E (pt) Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados
NO20030985L (no) Behandling av betennelsestilstander
DK1231908T3 (da) Farmaceutisk præparat, der omfatter en NO-donorforbindelse samt anvendelse heraf
BR0008385A (pt) Laxantes efervescentes
DE69831416D1 (de) Chinolin-harnstoff-derivate zur behandlung von entzugssyndrom und durch entzugssyndrom verursachten gehirnschaden
SE9700617D0 (sv) New composition
EP1200459A4 (de) Verbindungen zur behandlung von infektionskrankheiten und störungen des immunsystems sowie methoden ihrer anwendung
RU98112055A (ru) Способ лечения заболеваний слизистой оболочки рта у больных с вторичными иммунодефицитами
RU2001134578A (ru) Способ лечения хронических заболеваний кишечника ассоциированных с дисбактериозом
CO4180553A1 (es) Composiciones para el tratamiento de la peridontitis adulta

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties